Rapamycin-d3 – 1 mg

Brand:
Cayman
CAS:
392711-19-2
Storage:
-20
UN-No:
Non-Hazardous - /

Rapamycin-d3 is intended for use as an internal standard for the quantification of rapamycin (Item No. 13346) by GC- or LC-MS. Rapamycin is an allosteric inhibitor of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1).{45403} It interacts with FKBP prolyl isomerase 1A (FKBP12) to form a complex that binds to and inhibits the kinase activity of mTORC1. Rapamycin inhibits growth of Rh1 and Rh30 rhabdomyosarcoma cells in serum-free medium, with 50% inhibition observed at concentrations of 0.1 and 0.5 ng/ml, respectively, and increases apoptosis in these cells at 100 ng/ml.{45404} It also induces autophagy in a variety of cell types.{45403} Rapamycin inhibits IL-2-induced proliferation of IL-2-dependent T cells by 50% when used at concentrations less than 5 pM.{17469} Formulations containing rapamycin have been used as immunosuppressive agents in the prevention of organ transplant rejection.  

 

Out of stock

SKU: 22093 - Category:

Description

An internal standard for the quantification of rapamycin by GC- or LC-MS


Formal name: 7-O-demethyl-7-O-(methyl-d3)-rapamycin

Synonyms:  Sirolimus-d3

Molecular weight: 917.2

CAS: 392711-19-2

Purity: ≥99% deuterated forms (d1-d3)

Formulation: A powder


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|mTOR||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Autophagy||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling||Research Area|Cell Biology|Cell Signaling|PI3K/Akt/mTOR Signaling||Research Area|Cell Biology|Endomembrane System & Vesicular Trafficking|Autophagy||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Immunosuppressants